Last reviewed · How we verify
isoquercetin or quercetin
At a glance
| Generic name | isoquercetin or quercetin |
|---|---|
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 (PHASE2)
- Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States (EARLY_PHASE1)
- Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- isoquercetin or quercetin CI brief — competitive landscape report
- isoquercetin or quercetin updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI